Edwards Lifesciences Corporation (NYSE:EW) – Analysts at SunTrust Banks lifted their FY2017 earnings per share estimates for Edwards Lifesciences Corporation in a report issued on Wednesday. SunTrust Banks analyst B. Nudell now forecasts that the medical research company will earn $3.80 per share for the year, up from their previous forecast of $3.78. SunTrust Banks currently has a “Buy” rating and a $14.00 target price on the stock. SunTrust Banks also issued estimates for Edwards Lifesciences Corporation’s Q4 2017 earnings at $0.95 EPS, Q1 2018 earnings at $1.12 EPS, Q3 2018 earnings at $0.96 EPS, Q4 2018 earnings at $1.04 EPS, FY2018 earnings at $4.21 EPS, FY2019 earnings at $4.78 EPS, FY2020 earnings at $5.38 EPS and FY2021 earnings at $5.91 EPS.

Edwards Lifesciences Corporation (NYSE:EW) last announced its quarterly earnings data on Wednesday, July 26th. The medical research company reported $1.08 EPS for the quarter, topping the Zacks’ consensus estimate of $0.88 by $0.20. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The firm had revenue of $842.00 million during the quarter, compared to analyst estimates of $839.16 million. The business’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same period last year, the company posted $0.76 EPS.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at https://www.watchlistnews.com/brokers-issue-forecasts-for-edwards-lifesciences-corporations-fy2017-earnings-ew/1645345.html.

A number of other research analysts also recently issued reports on EW. Cowen and Company reiterated a “buy” rating and set a $135.00 price objective on shares of Edwards Lifesciences Corporation in a report on Thursday, October 12th. Barclays PLC reiterated an “equal weight” rating and set a $120.00 price objective on shares of Edwards Lifesciences Corporation in a report on Saturday, September 30th. Canaccord Genuity reiterated a “buy” rating and set a $155.00 price objective (up from $150.00) on shares of Edwards Lifesciences Corporation in a report on Sunday, July 30th. Jefferies Group LLC reiterated a “buy” rating and set a $115.00 price objective on shares of Edwards Lifesciences Corporation in a report on Friday, June 30th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $130.00 price objective (up from $118.00) on shares of Edwards Lifesciences Corporation in a report on Thursday, July 27th. Seven investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $120.75.

Shares of Edwards Lifesciences Corporation (NYSE:EW) opened at 113.08 on Friday. The stock’s 50 day moving average price is $111.15 and its 200 day moving average price is $111.91. The firm has a market capitalization of $23.88 billion, a price-to-earnings ratio of 34.30 and a beta of 0.62. Edwards Lifesciences Corporation has a one year low of $81.12 and a one year high of $121.45.

In other news, VP Larry L. Wood sold 18,960 shares of the stock in a transaction that occurred on Wednesday, August 30th. The stock was sold at an average price of $111.81, for a total transaction of $2,119,917.60. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Michael A. Mussallem sold 32,900 shares of the stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $114.80, for a total value of $3,776,920.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 201,161 shares of company stock valued at $22,826,072. Insiders own 2.13% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the company. ETF Managers Group LLC bought a new position in shares of Edwards Lifesciences Corporation during the second quarter worth approximately $112,000. Shine Investment Advisory Services Inc. bought a new position in shares of Edwards Lifesciences Corporation during the second quarter worth approximately $126,000. Cornerstone Advisors Inc. increased its stake in shares of Edwards Lifesciences Corporation by 25.1% during the second quarter. Cornerstone Advisors Inc. now owns 1,092 shares of the medical research company’s stock worth $129,000 after purchasing an additional 219 shares during the period. Alexandria Capital LLC increased its stake in shares of Edwards Lifesciences Corporation by 1.7% during the second quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock worth $136,000 after purchasing an additional 19 shares during the period. Finally, MPS Loria Financial Planners LLC bought a new position in shares of Edwards Lifesciences Corporation during the second quarter worth approximately $140,000. Institutional investors own 81.90% of the company’s stock.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Earnings History and Estimates for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.